Milestone payments and sale of product rights bring profit in second quarter Second quarter 2014, April - June · Net sales for April – June 2014 amounted to SEK 32 (12) million. · Earnings after tax for April – June 2014: SEK 3.7 (-9.4) million. · Earnings after tax per share for April – June before and after dilution: SEK 0.04 (-0.13). · Cash flow from current operations and investment activities for April – June 2014: SEK -25 (-37) million. Half year results 2014, January – June · Net sales for January – June 2014 amounted to SEK 34 (24) million. · Earnings after tax for January – June 2014: SEK -15 (-24) million. · Earnings after tax for January – June before and after dilution: SEK -0.17 ( -0.32). · Liquid funds as of 30 June 2014: SEK 74 (40) million. Cash flow from current operations and investment activities for January – June 2014: SEK -48 (-60) million. Important events in the second quarter and after the reporting period · In the second quarter BioInvent received SEK 63.9 million through a rights issue combined with a private placement. The rights issue was oversubscribed by 101% and amounted to SEK 48.9 million. The private placement of SEK 15 million was subscribed by Henrik Rhenman through Rhenman Healthcare Equity L / S and Peter Thelin through East Bay AB. · BioInvent sold back its rights to the drug candidate ADC-1013 to Alligator Bioscience AB to focus resources on the fully owned drug development candidates. · BioInvent was granted a U.S. patent for BI-505 and apoptosis-inducing ICAM-1 antibodies. The patent provides broad protection for BI-505 which is in a phase II study and which was developed using F.I.R.S.T.™, BioInvent's patented discovery platform for antibody drug candidates and cellular target structures. · BioInvent has received milestone payments from Bayer and Servier totaling EUR one million. The milestone payments are based on the development of antibodies identified from BioInvent’s n-CoDeR® antibody library. The milestone payments were triggered as Bayer enrolled the first patient in a phase I clinical trial and Servier reached in vivo proof of concept against a specific target structure. Comments from the CEO "In the second quarter, we demonstrated that we can generate significant revenue from our technology. We have scaled up our marketing efforts and seen a growing interest from international pharmaceutical and biotech companies for our development platform F.I.R.S.T™ and for our key pipeline projects. Our research programs are focused in immuno-oncology, the pharmaceutical market segment expected to become the largest pharmaceutical market in oncology with a value potential of over SEK 200 billion." says Michael Oredsson, CEO of BioInvent. Contact Any questions regarding this report will be answered by Michael Oredsson, CEO, phone.+46 (0)46 286 85 67, mobile +46 (0)707 18 89 30. The report is also available at www.bioinvent.com Information disclosed in this half year report is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 24 July, 2014. BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier and Xoma.
BioInvent Interim Report 1 January – 30 June 2014
Top 10 Most Recent News Articles
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal
Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...
Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market
Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...
Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue ReadingTop 5 Most Recently Viewed Articles
Geotab's Vision for Addressing Youth Unemployment Through Internships
Geotab's Commitment to Future Workforce Development As Geotab Inc. celebrates its remarkable 25th anniversary, the company is taking bold steps to enhance internship opportunities for young graduates entering an increasingly competitive job market. With youth unemployment rates rising in North America, organizations like Geotab are not only addressing a pressing social...
Continue Reading
Joaquín de Valenzuela Joins nCino as EMEA Managing Director
Joaquín de Valenzuela Takes the Helm at nCino for EMEA nCino, Inc. (NASDAQ: NCNO), a leader in intelligent banking solutions, is proud to announce the appointment of Joaquín de Valenzuela as the Managing Director for the EMEA region. This significant hire underscores the company's dedication to bolstering its growth trajectory and expanding its influence across the...
Continue Reading
Aya Gold & Silver Unveils Stunning Silver Drilling Results
Aya Gold & Silver Reports New Silver Drilling Success Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) is excited to share outstanding silver drill results from its ongoing exploration at the Zgounder Silver Mine. The results not only highlight high-quality silver finds but also identify several promising new targets in the Zgounder Regional area. Drilling Highlights and...
Continue Reading
Nvidia's Deep Roots in China's Tech Landscape Drive AI Success
Nvidia's Deep Roots in China's Tech Landscape Drive AI Success Nvidia Corp. CEO Jensen Huang recently highlighted the significant impact of China’s technology ecosystem on Nvidia’s growth during a keynote address at a major university event. His reflections underline a robust relationship spanning over 25 years, which has been pivotal in shaping Nvidia into a leading...
Continue Reading
Aalberts N.V. Achieves Strategic Growth Despite Market Challenges
Aalberts N.V. Reports First Quarter Results In the latest financial report, Aalberts N.V. showcased its first quarter outcomes, revealing revenues of EUR 778.3 million. This figure marks a 3.3% decline in organic revenue compared to the same period last year, pointing to ongoing challenges within the market. Operational Performance and Margin Insights The company's EBITA...
Continue Reading